A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity
International Journal of Molecular Sciences · 30.04.2026 · 27 (9) · 4058
DOI: 10.3390/ijms27094058 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.04.2026. Verfasst von Joonho Kong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea. Hauptthemen laut MEDLINE: Pyridazines, Imidazoles, Transcriptome, Protein Kinase Inhibitors. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bio&Medical Technology Development Program of the National Research Foundation (NRF), Bio&Medical Technology Development Program.
Abstract (Originalsprache)
Ponatinib, a third-generation BCR::ABL1 inhibitor, has antileukemic activity but is associated with cardiovascular toxicity, for which transcriptome-level responses remain incompletely characterized. Here, we defined a ponatinib-associated transcriptomic signature and examined its mechanistic implications using two public RNA sequencing (RNA-Seq) datasets: GSE186341 (11 cancer cell lines treated with kinase inhibitors) and GSE217421 (induced pluripotent stem cell (iPSC)-derived cardiomyocytes treated with approved drugs). Principal component analysis (PCA) and k-means clustering were used to define expression-based subgroups of vehicle-treated (DMSO) controls. DESeq2, followed by fixed-effect meta-analysis, estimated subgroup-specific treatment effects and pooled effect estimates across subgroups. In GSE186341, we identified 2639 meta-analytic differentially expressed genes (meta-DEGs). Among these, 81 genes were also differentially expressed in GSE217421 after ponatinib treatment, identifying an overlapping gene set across datasets. In contrast, imatinib showed no overlap with these 81 genes under the same cross-dataset analysis framework. Cardiotoxicity-relevant functions were represented by directionally consistent genes linked to cardiac repolarization-associated ion handling (KCNN3), insulin-responsive metabolic regulation (FOXO1, HK2), cyclic adenosine monophosphate (cAMP)-responsive stress signaling (RAPGEF3), and mitochondrial homeostasis and redox regulation (MCL1, GCH1). Collectively, these results define a ponatinib-associated transcriptomic signature and nominate cross-dataset transcript-level candidates for subsequent mechanistic and experimental validation in ponatinib-associated cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
- Division of Hematology-Oncology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
- Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
ORCID-Profile: Jee Hyun Kong, Taesic Lee
Förderung
- Bio&Medical Technology Development Program of the National Research Foundation (NRF)
- Bio&Medical Technology Development Program
Zitieren
APA
Kong, J., Jang, J., Kong, J. H., & Lee, T. (2026). A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity. International Journal of Molecular Sciences, 27(9), 4058. https://doi.org/10.3390/ijms27094058
Vancouver
Kong J, Jang J, Kong JH, Lee T. A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity. International Journal of Molecular Sciences. 2026;27(9):4058. doi:10.3390/ijms27094058
BibTeX
@article{Kong2026,
author = {Kong, Joonho and Jang, Jaeyeon and Kong, Jee Hyun and Lee, Taesic},
title = {A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {9},
pages = {4058},
doi = {10.3390/ijms27094058}
}
EUVIMED